IGI Laboratories, Inc. has acquired two previously marketed ophthalmic drug products, along with the to right to acquire three additional previously marketed injectable drugs from affiliates of Valeant Pharmaceuticals. All of the products have been approved by the FDA as abbreviated new drug applications (ANDAs) or new drug applications (NDAs). The current U.S. market for the therapeutic areas these products were indicated for is estimated at $38 million, as of August 2014, according tot IMS Hea...